Publication | Open Access

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Hematological MalignancyLymphoid NeoplasiaAutoimmune DiseaseChop TherapyPoor OutcomeMedicineMalignant Blood DisorderImmunologyCd5 ExpressionPathologyImmune Checkpoint InhibitorAdult T-cell Leukemia-lymphomaImmunotherapyOncology